Neurology Central

Journal Watch: aducanumab reduces amyloid aggregates and hints at cognitive benefit in a Phase Ib clinical trial

On 1 September 2016, Biogen (MA, USA) published the results of their Phase Ib clinical trial in Nature. The double-blind, placebo-controlled study of 165 prodromal and mild Alzheimer’s disease (AD) patients took newspaper headlines by storm and instilled hope for the public and clinical scientists alike. However, whilst the results of this clinical trial are promising, aducanumab is far from a silver bullet for AD.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.